Spasticity

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Spasticity is an imbalance of the sensorimotor system that demonstrates an increased response to a velocity dependent stretch of the muscle tendon resulting from hyperexcitable muscle stretch reflexes. Spasticity is a small part of the upper motor neuron syndrome composed of increased tone, hyperactive reflexes, weakness, and poor coordination. This hyperexcitability of the alpha motor neuron pool results in the characteristic positive phenomena associated with spasticity. Typically, the upper motor neuron syndrome is characterized by positive and negative symptoms. The positive symptoms are typically the target of therapy with either medication or injections of botulinum toxin. The negative symptoms are due to the damage of the corticospinal tract resulting in weakness, loss of fine motor control, and the Babinski sign. Understanding the source of the positive and negative symptoms can assist the physician in designing a treatment plan tailored for the individual patient. When accessing and treating a patient with spasticity, regardless of the cause, the physician must have knowledge of the patient's lifestyle and the current disability that the patient faces in his or her day-to-day activities. The development of additional tools to treat spasticity is heavily dependent on an improved understanding of pathophysiological mechanisms at both the neurophysiological and the molecular level. Animal models are an indispensable part of spasticity research and are a vital part of future advances in this important area of neuroscience investigation.

Original languageEnglish (US)
Title of host publicationMovement Disorders
PublisherElsevier Inc.
Pages679-686
Number of pages8
ISBN (Print)9780120883820
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Motor Neurons
Babinski's Reflex
Physicians
Stretch Reflex
Muscles
Pyramidal Tracts
Botulinum Toxins
Neurosciences
Tendons
Reflex
Life Style
Animal Models
Injections
Therapeutics
Research

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Brashear, A. (2005). Spasticity. In Movement Disorders (pp. 679-686). Elsevier Inc.. https://doi.org/10.1016/B978-012088382-0/50059-1

Spasticity. / Brashear, Allison.

Movement Disorders. Elsevier Inc., 2005. p. 679-686.

Research output: Chapter in Book/Report/Conference proceedingChapter

Brashear, A 2005, Spasticity. in Movement Disorders. Elsevier Inc., pp. 679-686. https://doi.org/10.1016/B978-012088382-0/50059-1
Brashear A. Spasticity. In Movement Disorders. Elsevier Inc. 2005. p. 679-686 https://doi.org/10.1016/B978-012088382-0/50059-1
Brashear, Allison. / Spasticity. Movement Disorders. Elsevier Inc., 2005. pp. 679-686
@inbook{c309b9b1e9864e57b722736d38c38845,
title = "Spasticity",
abstract = "Spasticity is an imbalance of the sensorimotor system that demonstrates an increased response to a velocity dependent stretch of the muscle tendon resulting from hyperexcitable muscle stretch reflexes. Spasticity is a small part of the upper motor neuron syndrome composed of increased tone, hyperactive reflexes, weakness, and poor coordination. This hyperexcitability of the alpha motor neuron pool results in the characteristic positive phenomena associated with spasticity. Typically, the upper motor neuron syndrome is characterized by positive and negative symptoms. The positive symptoms are typically the target of therapy with either medication or injections of botulinum toxin. The negative symptoms are due to the damage of the corticospinal tract resulting in weakness, loss of fine motor control, and the Babinski sign. Understanding the source of the positive and negative symptoms can assist the physician in designing a treatment plan tailored for the individual patient. When accessing and treating a patient with spasticity, regardless of the cause, the physician must have knowledge of the patient's lifestyle and the current disability that the patient faces in his or her day-to-day activities. The development of additional tools to treat spasticity is heavily dependent on an improved understanding of pathophysiological mechanisms at both the neurophysiological and the molecular level. Animal models are an indispensable part of spasticity research and are a vital part of future advances in this important area of neuroscience investigation.",
author = "Allison Brashear",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/B978-012088382-0/50059-1",
language = "English (US)",
isbn = "9780120883820",
pages = "679--686",
booktitle = "Movement Disorders",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Spasticity

AU - Brashear, Allison

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Spasticity is an imbalance of the sensorimotor system that demonstrates an increased response to a velocity dependent stretch of the muscle tendon resulting from hyperexcitable muscle stretch reflexes. Spasticity is a small part of the upper motor neuron syndrome composed of increased tone, hyperactive reflexes, weakness, and poor coordination. This hyperexcitability of the alpha motor neuron pool results in the characteristic positive phenomena associated with spasticity. Typically, the upper motor neuron syndrome is characterized by positive and negative symptoms. The positive symptoms are typically the target of therapy with either medication or injections of botulinum toxin. The negative symptoms are due to the damage of the corticospinal tract resulting in weakness, loss of fine motor control, and the Babinski sign. Understanding the source of the positive and negative symptoms can assist the physician in designing a treatment plan tailored for the individual patient. When accessing and treating a patient with spasticity, regardless of the cause, the physician must have knowledge of the patient's lifestyle and the current disability that the patient faces in his or her day-to-day activities. The development of additional tools to treat spasticity is heavily dependent on an improved understanding of pathophysiological mechanisms at both the neurophysiological and the molecular level. Animal models are an indispensable part of spasticity research and are a vital part of future advances in this important area of neuroscience investigation.

AB - Spasticity is an imbalance of the sensorimotor system that demonstrates an increased response to a velocity dependent stretch of the muscle tendon resulting from hyperexcitable muscle stretch reflexes. Spasticity is a small part of the upper motor neuron syndrome composed of increased tone, hyperactive reflexes, weakness, and poor coordination. This hyperexcitability of the alpha motor neuron pool results in the characteristic positive phenomena associated with spasticity. Typically, the upper motor neuron syndrome is characterized by positive and negative symptoms. The positive symptoms are typically the target of therapy with either medication or injections of botulinum toxin. The negative symptoms are due to the damage of the corticospinal tract resulting in weakness, loss of fine motor control, and the Babinski sign. Understanding the source of the positive and negative symptoms can assist the physician in designing a treatment plan tailored for the individual patient. When accessing and treating a patient with spasticity, regardless of the cause, the physician must have knowledge of the patient's lifestyle and the current disability that the patient faces in his or her day-to-day activities. The development of additional tools to treat spasticity is heavily dependent on an improved understanding of pathophysiological mechanisms at both the neurophysiological and the molecular level. Animal models are an indispensable part of spasticity research and are a vital part of future advances in this important area of neuroscience investigation.

UR - http://www.scopus.com/inward/record.url?scp=84882293647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882293647&partnerID=8YFLogxK

U2 - 10.1016/B978-012088382-0/50059-1

DO - 10.1016/B978-012088382-0/50059-1

M3 - Chapter

AN - SCOPUS:84882293647

SN - 9780120883820

SP - 679

EP - 686

BT - Movement Disorders

PB - Elsevier Inc.

ER -